Markus Reinholz, Markus Heppt, Julia K Tietze, Thomas Ruzicka, Gerd G Gauglitz, Jürgen Schauber
{"title":"给编辑的信:外用0.5%溴胺凝胶来掩盖未成熟疤痕的红肿。","authors":"Markus Reinholz, Markus Heppt, Julia K Tietze, Thomas Ruzicka, Gerd G Gauglitz, Jürgen Schauber","doi":"10.3315/jdcr.2015.1210","DOIUrl":null,"url":null,"abstract":"<p><p>Cutaneous scars develop as a result of a defective wound healing process. Scars are commonly visible as erythematous, sometimes disfiguring lesions which might be stigmatizing for the affected patient. Only a few therapies to improve the appearance of scars are available. Recently, brimonidine - a selective α2-receptor-agonist which causes vasoconstriction of small cutaneous vessels - was approved for the treatment of erythemato-telangiectatic rosacea. Topical brimonidine might also be helpful to improve redness of immature scars. Here we report on the effect of brimonidine 0.5% gel on a flat, erythematous scar in a 25-year-old female patient. Whitening of the scar could be observed immediately after application of brimonidine 0.5% gel and a good clinical result was observed within one hour. This effect lasted for up to three hours. We conclude that brimonidine 0.5% gel is a suitable topical therapy to reduce erythema in visible cutaneous scars. </p>","PeriodicalId":15601,"journal":{"name":"Journal of dermatological case reports","volume":"9 3","pages":"87-8"},"PeriodicalIF":0.0000,"publicationDate":"2015-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619167/pdf/jdcr-09-087.pdf","citationCount":"3","resultStr":"{\"title\":\"Photoletter to the editor: Topical 0.5% brimonidine gel to camouflage redness of immature scars.\",\"authors\":\"Markus Reinholz, Markus Heppt, Julia K Tietze, Thomas Ruzicka, Gerd G Gauglitz, Jürgen Schauber\",\"doi\":\"10.3315/jdcr.2015.1210\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cutaneous scars develop as a result of a defective wound healing process. Scars are commonly visible as erythematous, sometimes disfiguring lesions which might be stigmatizing for the affected patient. Only a few therapies to improve the appearance of scars are available. Recently, brimonidine - a selective α2-receptor-agonist which causes vasoconstriction of small cutaneous vessels - was approved for the treatment of erythemato-telangiectatic rosacea. Topical brimonidine might also be helpful to improve redness of immature scars. Here we report on the effect of brimonidine 0.5% gel on a flat, erythematous scar in a 25-year-old female patient. Whitening of the scar could be observed immediately after application of brimonidine 0.5% gel and a good clinical result was observed within one hour. This effect lasted for up to three hours. We conclude that brimonidine 0.5% gel is a suitable topical therapy to reduce erythema in visible cutaneous scars. </p>\",\"PeriodicalId\":15601,\"journal\":{\"name\":\"Journal of dermatological case reports\",\"volume\":\"9 3\",\"pages\":\"87-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619167/pdf/jdcr-09-087.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of dermatological case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3315/jdcr.2015.1210\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of dermatological case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3315/jdcr.2015.1210","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Photoletter to the editor: Topical 0.5% brimonidine gel to camouflage redness of immature scars.
Cutaneous scars develop as a result of a defective wound healing process. Scars are commonly visible as erythematous, sometimes disfiguring lesions which might be stigmatizing for the affected patient. Only a few therapies to improve the appearance of scars are available. Recently, brimonidine - a selective α2-receptor-agonist which causes vasoconstriction of small cutaneous vessels - was approved for the treatment of erythemato-telangiectatic rosacea. Topical brimonidine might also be helpful to improve redness of immature scars. Here we report on the effect of brimonidine 0.5% gel on a flat, erythematous scar in a 25-year-old female patient. Whitening of the scar could be observed immediately after application of brimonidine 0.5% gel and a good clinical result was observed within one hour. This effect lasted for up to three hours. We conclude that brimonidine 0.5% gel is a suitable topical therapy to reduce erythema in visible cutaneous scars.